Dopamine replacement therapy

This page covers all Dopamine replacement therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Aromatic amino acid decarboxylase (AADC); dopamine pathway, Dopamine pathway; aromatic amino acid decarboxylase inhibition.

Targets

Aromatic amino acid decarboxylase (AADC); dopamine pathway · Dopamine pathway; aromatic amino acid decarboxylase inhibition

Marketed (1)

• carbidopa-levodopa (Sinemet) · Baylor College of Medicine · Neurology
  Carbidopa inhibits peripheral decarboxylation of levodopa, allowing more levodopa to reach the brain where it is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease.

Phase 3 pipeline (1)

• Oral IR-LD/CD · NeuroDerm Ltd. · Neurology
  Oral IR-LD/CD is a levodopa/carbidopa combination that increases dopamine levels in the brain by delivering levodopa with carbidopa, a decarboxylase inhibitor, to treat motor symptoms of Parkinson's disease.